Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) Stock Competitors & Peer Comparison

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, RPRX has a market cap of 25.2B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while RPRX trades at $56.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 10.81. In terms of profitability, CPD's ROE is N/A, compared to RPRX's ROE of +0.11%. Regarding short-term risk, CPD is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for CPD.Check RPRX's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, CORT has a market cap of 12B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while CORT trades at $110.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 316.49. In terms of profitability, CPD's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, CPD is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for CPD.Check CORT's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, CPD's ROE is N/A, compared to WBA's ROE of -0.42%. Regarding short-term risk, CPD is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CPD.Check WBA's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, LQDA has a market cap of 8B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while LQDA trades at $90.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 644.43. In terms of profitability, CPD's ROE is N/A, compared to LQDA's ROE of +0.47%. Regarding short-term risk, CPD is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for CPD.Check LQDA's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, KNSA has a market cap of 5.8B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while KNSA trades at $76.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 84.51. In terms of profitability, CPD's ROE is N/A, compared to KNSA's ROE of +0.14%. Regarding short-term risk, CPD is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for CPD.Check KNSA's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while TRLV trades at $8.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas TRLV's P/E ratio is -20.83. In terms of profitability, CPD's ROE is N/A, compared to TRLV's ROE of -0.44%. Regarding short-term risk, CPD is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for CPD.Check TRLV's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas HROWL's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to HROWL's ROE of -0.34%. Regarding short-term risk, CPD is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CPD.Check HROWL's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas HROWM's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to HROWM's ROE of -0.34%. Regarding short-term risk, CPD is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CPD.Check HROWM's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, CUVL has a market cap of 336.6M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while CUVL trades at $6.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas CUVL's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to CUVL's ROE of N/A. Regarding short-term risk, CPD is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for CPD.Check CUVL's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, LFMD has a market cap of 172.2M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while LFMD trades at $3.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas LFMD's P/E ratio is -7.12. In terms of profitability, CPD's ROE is N/A, compared to LFMD's ROE of -1.79%. Regarding short-term risk, CPD is less volatile compared to LFMD. This indicates lower risk in terms of short-term price fluctuations for CPD.Check LFMD's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, LFMDP has a market cap of 160M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while LFMDP trades at $23.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas LFMDP's P/E ratio is -722.96. In terms of profitability, CPD's ROE is N/A, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, CPD is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for CPD.Check LFMDP's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, CIRC has a market cap of 65.1M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while CIRC trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas CIRC's P/E ratio is -1.64. In terms of profitability, CPD's ROE is N/A, compared to CIRC's ROE of +0.00%. Regarding short-term risk, CPD is less volatile compared to CIRC. This indicates lower risk in terms of short-term price fluctuations for CPD.Check CIRC's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, CPD's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, CPD is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CPD.Check RAD's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CPD's ROE is N/A, compared to GLTO's ROE of -1.22%. Regarding short-term risk, CPD is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CPD.Check GLTO's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, SCYX has a market cap of 33M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while SCYX trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.53. In terms of profitability, CPD's ROE is N/A, compared to SCYX's ROE of -0.57%. Regarding short-term risk, CPD is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for CPD.Check SCYX's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, NSRX has a market cap of 29.8M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while NSRX trades at $3.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas NSRX's P/E ratio is -4.80. In terms of profitability, CPD's ROE is N/A, compared to NSRX's ROE of +0.00%. Regarding short-term risk, CPD is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for CPD.Check NSRX's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, SDEV has a market cap of 28.2M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while SDEV trades at $1.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas SDEV's P/E ratio is -0.18. In terms of profitability, CPD's ROE is N/A, compared to SDEV's ROE of +7.90%. Regarding short-term risk, CPD is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for CPD.Check SDEV's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, BFRI has a market cap of 16.3M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while BFRI trades at $1.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -1.19. In terms of profitability, CPD's ROE is N/A, compared to BFRI's ROE of -4.77%. Regarding short-term risk, CPD is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for CPD.Check BFRI's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CPD's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CPD is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for CPD.Check CJJD's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, CPD's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, CPD is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CPD.Check SSY's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, POM has a market cap of 5.9M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while POM trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas POM's P/E ratio is -0.17. In terms of profitability, CPD's ROE is N/A, compared to POM's ROE of +0.16%. Regarding short-term risk, CPD is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CPD.Check POM's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, PAVS has a market cap of 5.3M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while PAVS trades at $6.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas PAVS's P/E ratio is -0.07. In terms of profitability, CPD's ROE is N/A, compared to PAVS's ROE of -0.27%. Regarding short-term risk, CPD is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for CPD.Check PAVS's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, HKPD has a market cap of 4.6M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while HKPD trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas HKPD's P/E ratio is -7.01. In terms of profitability, CPD's ROE is N/A, compared to HKPD's ROE of -0.14%. Regarding short-term risk, CPD is less volatile compared to HKPD. This indicates lower risk in terms of short-term price fluctuations for CPD.Check HKPD's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, AIXC has a market cap of 4.3M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while AIXC trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas AIXC's P/E ratio is -0.09. In terms of profitability, CPD's ROE is N/A, compared to AIXC's ROE of -0.94%. Regarding short-term risk, CPD is less volatile compared to AIXC. This indicates lower risk in terms of short-term price fluctuations for CPD.Check AIXC's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CPD's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CPD is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CPD.Check MDVL's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, CPD is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CPD.Check ATNFW's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CPD's ROE is N/A, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, CPD is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for CPD.Check BGMSP's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while BGMS trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.26. In terms of profitability, CPD's ROE is N/A, compared to BGMS's ROE of -0.51%. Regarding short-term risk, CPD is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for CPD.Check BGMS's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CPD's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CPD is less volatile compared to AZNH. This indicates lower risk in terms of short-term price fluctuations for CPD.Check AZNH's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CPD's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CPD is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CPD.Check LFLYW's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, SBFMW has a market cap of 175.2K. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while SBFMW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas SBFMW's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, CPD is less volatile compared to SBFMW. This indicates lower risk in terms of short-term price fluctuations for CPD.Check SBFMW's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CPD's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CPD is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CPD.Check ESRX's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, POZN has a market cap of 0. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, CPD is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CPD.Check POZN's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, OREX has a market cap of 0. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas OREX's P/E ratio is -0.14. In terms of profitability, CPD's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, CPD is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CPD.Check OREX's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CPD's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CPD is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CPD.Check IPXL's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CPD's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CPD is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CPD.Check SHPG's competition here